Equities research analysts at Zacks Research lowered their Q1 2025 earnings per share estimates for shares of United ...

Liquidia Corporation has announced a significant financial move by amending its agreement with Healthcare Royalty to ...

During the last three months, 4 analysts shared their evaluations of Liquidia LQDA, revealing diverse outlooks from bullish ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $98.62, a high estimate of $110.00, and a low estimate of $90.00. Witnessing a positive shift, the current ...

In the 10-K report, Liquidia Corporation reported a net loss of $130.4 million for the year ended December 31, 2024, compared ...

Corsair Pharma is planning a Phase 1 clinical trial of its treprostinil skin patch as a treatment for pulmonary arterial hypertension (PAH).

Targeting final FDA approval of YUTREPIA™ after expiration of regulatory exclusivity on May 23, 2025Advancing pipeline of inhaled treprostinil ...

Under the terms of the Sixth Amendment, Liquidia will receive $25.0 million at closing with the potential to receive two additional tranches of funding: $50.0 million upon the first commercial sale of ...

Corsair Pharma Announces Successful Completion of Preclinical Program for Its Treprostinil Prodrug Transdermal System ...

The leading Pulmonary Arterial Hypertension Companies such as Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, ...

M&T Bank Corp increased its stake in shares of United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 9.4% during the 4th ...

The study presents valuable findings on the molecular mechanisms of glucose-stimulated insulin secretion from pancreatic islets, focusing on the main regulatory elements of the signaling pathway in ...